Labeling Stem Cells with a New Hybrid Bismuth/Carbon Nanotube Contrast Agent for X-Ray Imaging

The poor retention and survival of cells after transplantation to solid tissue represent a major obstacle for the effectiveness of stem cell-based therapies. The ability to track stem cells in vivo can lead to a better understanding of the biodistribution of transplanted cells, in addition to improv...

Descripción completa

Detalles Bibliográficos
Autores principales: Hernández-Rivera, Mayra, Cho, Stephen Y., Moghaddam, Sakineh E., Cheong, Benjamin Y., Cabreira-Hansen, Maria da Graça, Willerson, James T., Perin, Emerson C., Wilson, Lon J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6594287/
https://www.ncbi.nlm.nih.gov/pubmed/31281232
http://dx.doi.org/10.1155/2019/2183051
Descripción
Sumario:The poor retention and survival of cells after transplantation to solid tissue represent a major obstacle for the effectiveness of stem cell-based therapies. The ability to track stem cells in vivo can lead to a better understanding of the biodistribution of transplanted cells, in addition to improving the analysis of stem cell therapies' outcomes. Here, we described the use of a carbon nanotube-based contrast agent (CA) for X-ray computed tomography (CT) imaging as an intracellular CA to label bone marrow-derived mesenchymal stem cells (MSCs). Porcine MSCs were labeled without observed cytotoxicity. The CA consists of a hybrid material containing ultra-short single-walled carbon nanotubes (20–80 nm in length, US-tubes) and Bi(III) oxo-salicylate clusters which contain four Bi(3+) ions per cluster (Bi(4)C). The CA is thus abbreviated as Bi(4)C@US-tubes.

Ejemplares similares